Finanzas de Phibro Animal Health Corp (PAHC)PAHCPhibro Animal Health Corp

Phibro Animal Health Corp (PAHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MFAs and Other, accounting for 53.6% of total sales, equivalent to $195.20M. Other significant revenue streams include Nutritional specialties and Vaccines. Understanding this composition is critical for investors evaluating how PAHC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Phibro Animal Health Corp maintains a gross margin of 31.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.69%, while the net margin is 5.47%. These profitability ratios, combined with a Return on Equity (ROE) of 29.72%, provide a clear picture of how effectively PAHC converts its operational activities into shareholder value.

In the context of the broader market, PAHC competes directly with industry leaders such as RARE and GPCR. With a market capitalization of $1.58B, it holds a leading position in the sector. When comparing efficiency, PAHC's gross margin of 31.73% stands against RARE's 84.11% and GPCR's N/A. Such benchmarking helps identify whether Phibro Animal Health Corp is trading at a premium or discount relative to its financial performance.

Phibro Animal Health has shown consistent revenue growth, with Q4 2026 net income of $35 million and total sales for FY 2026 increasing by 17%. The gross margin has remained stable around 33%, indicating solid profitability.